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Raf-1 is a critical downstream target of Ras and con-
tains two distinct domains that bind Ras. The first Ras-
binding site (RBS1) in Raf-1 has been shown to be essen-
tial for Ras-mediated translocation of Raf-1 to the
plasma membrane, whereas the second site, in the Raf-1
cysteine-rich domain (Raf-CRD), has been implicated in
regulating Raf kinase activity. While recognition ele-
ments that promote RaszRBS1 complex formation have
been characterized, relatively little is known about Ras/
Raf-CRD interactions. In this study, we have character-
ized interactions important for Ras binding to the Raf-
CRD. Reconciling conflicting reports, we found that
these interactions are essentially independent of the
guanine nucleotide bound state, but instead, are en-
hanced by post-translational modification of Ras. Spe-
cifically, our findings indicate that Ras farnesylation is
sufficient for stable association of Ras with the Raf-
CRD. Furthermore, we have also identified a Raf-CRD
variant that is impaired specifically in its interactions
with Ras. NMR data also suggests that residues proxi-
mal to this mutation site on the Raf-CRD form contacts
with Ras. This Raf-CRD mutant impairs the ability of
Ras to activate Raf kinase, thereby providing additional
support that Ras interactions with the Raf-CRD are im-
portant for Ras-mediated activation of Raf-1.
The best characterized Ras effector is the serine/threonine
kinase Raf-1. Raf-1 propagates its signal via activation of the
serine/threonine kinase MEK,1 which in turn, phosphorylates
its substrate MAPK. MAPK then translocates to the nucleus,
where it activates a variety of proteins including transcription
factors (1, 2).
The amino terminus of Raf-1 contains two conserved regions
(CR1 and CR2) that have been postulated to negatively regu-
late the carboxyl-terminal kinase domain (CR3) (reviewed in
Refs. 1 and 3). While CR2 (residues 255–268) is rich in serine
and threonine residues that become phosphorylated during
Raf-1 activation (4, 5), CR1 of Raf-1 contains two Ras-binding
domains. The first Ras-binding site encompasses Raf-1 resi-
dues 55–131 (Ras-binding site 1; RBS1) (6–8), with the second
binding site located in the cysteine-rich domain (Raf-1 residues
139–184, Raf-CRD) (9–11).
Ras was initially believed to function by translocating Raf to
the plasma membrane via interactions with RBS1 where other
Ras-independent events, then led to Raf kinase activation.
These Ras-independent activation events are thought to re-
quire modulation of both intra- and intermolecular interactions
as well as Raf-1 phosphorylation (2, 12, 13). Although details
regarding Raf activation upon Ras-mediated membrane re-
cruitment of Raf still remain elusive, it has become apparent
that even the role of Ras in mediating Raf-1 activation is more
complex than originally envisioned. In fact, recent evidence
supports a dual role for Ras in both membrane localization and
allosteric activation of Raf-1. While Ras interaction with the
RBS1 has been shown to facilitate membrane recruitment, we
and others have found that interactions between Ras and the
Raf-CRD play an important role in allosteric activation of Raf-1
by Ras (9–11, 14, 15). However, the recognition elements in-
volved in binding of Ras to the Raf-CRD, and how this binding
event is coupled to Raf kinase regulation is not clear. In this
study, we have employed site-directed mutagenesis, binding
analyses, in vivo Raf kinase assays, and NMR structural anal-
yses to elucidate interactions important for RaszRaf-CRD com-
plex formation and the functional role these binding interac-
tions play in regulation of Raf kinase activity.
Multiple regions of Ras appear to be involved in promoting
binding interactions with the Raf-1 amino terminus. The bind-
ing of GTP to Ras causes a conformational change in two
regions, commonly referred to as switch I and switch II (16–
18). The GTP-dependent conformation of switch I is critical for
high affinity interaction between Ras and RBS1 (19). However,
conflicting findings exist on whether the CRD can bind Ras in
the absence of post-translational modification, and whether the
interaction displays guanine nucleotide dependence (9, 10).
Regions flanking switch I appear important for mediating, at
least in part, Ras/Raf-CRD interactions (10, 11), and may ex-
plain the weak GTP dependence we previously observed for the
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unmodified Ras/Raf-CRD interaction (10). Other groups re-
ported that post-translational modification of Ras was essen-
tial for stable association with the Raf-CRD as well as Ras-
mediated activation of Raf-1, and that this interaction was
independent of the nucleotide bound state of Ras (10, 14).
However, these conflicting reports were based on results ob-
tained from distinct and non-quantitative binding assays,
where the ability to detect an interaction depends on the bind-
ing kinetics and assays employed. To resolve this apparent
discrepancy, we have employed a fluorescence-based quantita-
tive assay to determine the apparent dissociation constant
between lipid modified and non-modified GTP- and GDP-bound
Ras with the Raf-CRD.
Processed forms of both Ha-Ras and K-Ras appear necessary
for in vitro and in vivo Ras-mediated activation of Raf-1 (14, 15,
20–23). Carboxyl-terminal processing differs in Ha-, K-, and
N-Ras, and involves multiple modifications, including farnesy-
lation, palmitoylation, carboxyl-terminal cleavage, and carbox-
yl-methylation (24). One common lipid modification, however,
is farnesylation of the CAAX cysteine (20, 21). To assess
whether farnesylation of Ras alone is required for stable asso-
ciation with the Raf-CRD, we prepared farnesylated Ha-Ras in
vitro using purified bacterially expressed Ha-Ras-(1–189) and
recombinant farnesyl transferase. We then compared the bind-
ing of farnesylated to non-farnesylated bacterial expressed full-
length Ha-Ras. While unmodified Ras showed a weak but de-
tectable binding interaction with the Raf-CRD, higher affinity
association was observed with farnesylated Ras. We had pre-
viously observed a weak, preferential binding of GTP-bound
Ras relative to GDP-bound Ras to the Raf-CRD, when Ras is
not processed by ELISA (11). Consistent with our previous
observations, binding interactions between unprocessed Ras
and the Raf-CRD do show a GTP dependence in our fluores-
cence-based assay. However, we observe little, if any, prefer-
ence for GTP-bound Ras when Ras is farnesylated. This is in
contrast to the strong GTP dependence observed for the Ras/
Raf-RBS1 interaction (25).
While regions of Ras involved in Ras/RBS1 interactions have
been characterized, relatively little is known about Raf-CRD
residues important for associating with Ras. To elucidate res-
idues of the Raf-CRD important for Ras binding, we made
Raf-CRD mutations at conserved surface-exposed residues,
based on our previously determined NMR solution structure of
the Raf-CRD (26). Although we and others have identified Ras
mutants that impair interactions between Ras and Raf-CRD
(10, 11), Raf-CRD mutations that selectively interfere with
Raf-CRD binding to Ras without disrupting interactions with
the Raf-CRD’s other known ligands, phosphatidylserine (27)
and 14-3-3 proteins (28), have yet to be described. Here we
characterize a Raf-CRD variant, disrupted at a hydrophobic
patch on the surface of the Raf-CRD that is selectively impaired
in binding both farnesylated and non-farnesylated Ras. This
mutant, in the context of full-length Raf-1, is defective in Ras-
mediated Raf kinase activity in vivo, supporting earlier find-
ings that Ras interactions with the Raf-CRD are essential for
Ras mediated Raf-1 activation (11).
To characterize the regions of the Raf-CRD that interact with the
unprocessed form of Ras, we employed NMR spectroscopy to iden-
tify residues perturbed upon binding to unprocessed Ras. Results
from these structural studies are consistent with our mutagenesis
results and indicate that residues within the hydrophobic patch,
are important for Ras/Raf-CRD interactions.
EXPERIMENTAL PROCEDURES
Expression and Purification of Ras, 14-3-3, and Raf-1 Fragments—
Full-length Ha-Ras-(C118S/C181S/C184S) and Ha-Ras-(1–166) were
expressed and purified as described (29). The Raf-CRD mutants were
constructed using site-directed mutagenesis procedures described else-
where (28). The Raf fragments (Raf-CRD and Raf-CRD-(149/151) vari-
ant) were expressed as glutathione S-transferase (GST) fusion proteins
and purified by affinity chromatography as detailed in Ref. 27. 14-3-3z
(DNA construct was a gift from Dr. Haian Fu, Emory) was expressed in
bacteria as a His-tagged protein and purified as described (30).
In Vitro Farnesylation of Ha-Ras—Purified Ha-Ras-(C118S/C181S/
C184S) (0.4 mg/ml) was incubated in 20 mM Tris, pH 7.5, 5 mM MgCl2,
10 mM ZnSO4, 1 mM DTT, 30 mM nucleotide, 0.2% N-octyl glucopyrano-
side, 30 mM farnesylpyrophosphate (Biomol), 1 mM farnesyl transferase
(DNA construct was a gift from Dr. Pat Casey, Duke; protein purified as
described previously (31)) for 2 h at 37 °C. After incubation, FTase was
removed by the addition of nickel-agarose and the extent of Ha-Ras
farnesylation was assayed by SDS-PAGE. Farnesylated Ha-Ras was
separated from non-farnesylated Ha-Ras based on differential binding
to bind to a phenyl-Sepharose matrix. FTase-treated Ras was added to
a 5-ml phenyl-Sepharose CL-4B (Sigma) column that was previously
equilibrated in 50 mM HEPES, 5 mM MgCl2, 5 mM nucleotide, 1 mM DTT,
and 0.1% N-octyl glucopyranoside. The column was then washed with 2
column volumes of the same buffer and farnesylated protein eluted with
50 mM HEPES, 5 mM MgCl2, 5 mM nucleotide, 1 mM DTT, and 2.0%
N-octyl glucopyranoside (Sigma).
Synthesis of Mant-dGDP and Mant-GMP-P(NH)P—Mant-dGDP and
mant-GMP-P(NH)P were synthesized as described previously (mant
from Molecular Probes; dGDP and GMP-P(NH)P from Sigma) (32). The
reaction was usually .80% complete and mant-nucleotide was em-
ployed without further purification for incorporation into Ras.
Incorporation of Nucleotide into Ras—250 mM Ha-Ras (farnesylated
or non-farnesylated) was incubated for 2 h with gentle shaking in 32 mM
Tris, pH 8.0, 200 mM (NH4)2SO4, 0.1 mM EDTA, 5 mM DTT, 0.1% N-octyl
glucopyranoside, and 2.5 mM nucleotide at 25 °C. When mant-GMP-
P(NH)P labeling, 25 units of alkaline phosphatase linked to agarose
(Sigma) were added per milligram of Ha-Ras. The labeling reaction was
quenched by the addition of MgCl2 to a final concentration of 20 mM.
Ha-Ras was then exchanged into 20 mM Tris, pH 7.5, 50 mM NaCl, 5 mM
MgCl2, 1 mM DTT, 0.1% N-octyl glucopyranoside.
Fluorescence Spectroscopy—Fluorescence measurements were made
using an SLM-Aminco 8100 fluorescence spectrophotometer with an
excitation wavelength of 365 nm and an emission wavelength of 440
nm. Samples were under continuous stirring and thermostatted at
20 °C. Titrations were performed by adding known amounts of purified
Raf-CRD to 1 mM mant-dGDP or mant-GMP-P(NH)P-labeled Ha-Ras
(farnesylated or non-farnesylated) in 20 mM Tris, pH 7.5, 5 mM MgCl2,
20 mM ZnSO4, 1 mM DTT and monitoring the subsequent increase in
mant fluorescence intensity at 440 nm.
Ras/Raf-CRD Direct Binding Assay—200 pmol of the Raf-CRD frag-
ment (Raf-1 residues 136–187) fused to GST was immobilized on GSH-
agarose beads. The beads were then incubated with either 400 pmol of
full-length farnesylated Ha-Ras-GDP or 400 pmol of processed
K-Ras4B-GDP that had been purified from baculovirus-infected Sf9
cells (a gift from Gideon Bollag and David Stokoe, Onyx, Richmond,
CA). After gentle shaking to keep the beads suspended for 30 min in 100
ml of buffer (20 mM Hepes, pH 7.4, 5 mM MgCl2, 20 mM ZnSO4, 30 mM
GDP, 1 mM DTT, and 0.2% n-octyl b-D-glucopyranoside), the beads were
washed once in 1 ml of the same buffer. The protein was quantitated by
laser densitometry scanning of a Coomassie-stained SDS-PAGE, and
the ratios of Ras:GST-Raf were compared with the ratio of Ras:GST
alone. Assays were performed at least twice in duplicate.
ELISA-based Ras/Raf-CRD, 14-33/Raf-CRD Binding Assays, and
14-3-3/Phoshatidylserine Competition Studies—Binding interactions
between bacterially expressed Ha-Ras or 14-3-3 and the Raf-CRD were
assessed by ELISA as described (9). For 14-3-3/phosphatidylserine com-
petition studies, 200 pmol of GST-Raf-CRD and corresponding amounts
of GST were incubated for 20 min at room temperature with 400 pmol
of 14-3-3z in the presence and absence of 3 mg of dioleoyl phosphatidyl-
serine (Avanti Polar-Lipids, Inc.) and 1-palmitoyl-2-oleoyl phosphati-
dylcholine (Avanti Polar Lipids, Inc.) in 100 ml of 20 mM Hepes, pH 7.4,
5 mM MgCl2, 50 mM NaCl, 20 mM ZnSO4, 1 mM DTT, and 10 ml of
GSH-coated agarose beads. The presence of 14-3-3z was detected by
Western blotting using a 1:2500 dilution of a polyclonal 14-3-3z anti-
body (Santa Cruz Biotechnology, Inc.). The amount of 14-3-3 bound was
quantitated by laser densitometry. Assays were performed at least
twice in duplicate.
In Vivo Raf Kinase Assays—COS cells were transiently transfected
with 1 mg of mutant Raf and 1 mg of activated Ha-Ras, both in the vector
pCGN using LipofectAMINE (33). After 48 h, the cells were shifted to
1% serum and incubated overnight. The cells were then lysed (150 mM
NaCl, 50 mM Hepes, 1% Nonidet P-40, 0.5% deoxycholate, 5 mM EDTA,
Determinants and Functional Effects of Ras/Raf-CRD Binding 22173
50 mM sodium fluoride, 1 mM p-nitrophenyl phosphate, 5 mM benzami-
dine, 1 mM Na3VO4, and protease inhibitors) and the Raf immunopre-
cipitated with C-12 polyclonal antisera (Santa Cruz). The isolated ki-
nase mutants were then incubated with recombinant MEK (0.5 mg),
MAP kinase (0.5 mg), and myelin basic protein (MBP) (1 mg) in kinase
buffer (10 mM Tris, pH 7.5, 10 mM MgCl2, and 1 mM DTT) with
[g-32P]ATP at 30 °C for 20 min. The reaction was stopped by adding
SDS loading buffer and resolved by SDS-PAGE. Incorporation of 32P
into the MBP substrate was quantitated on a PhosphorImager. Expres-
sion of Ras and Raf mutants was examined by immunoblotting with
anti-HA antibody (BabCo).
NMR Sample Preparation—Uniformly 15N-enriched wild type Raf-
CRD or Raf-CRD-(149/151) protein was obtained by growing Esche-
richia coli with 99.8% 15NH4Cl (Isotec) as the sole nitrogen source (26).
The purified protein was concentrated to 2 ml in 30 mM Tris acetate at
pH 6.5, 75 mM Na2SO4, 10 mM ZnCl2, 1 mM DTT and exchanged into
NMR buffer (30 mM d11-Tris-d3-acetate (Isotec) at pH 6.5, 100 mM NaCl,
10 mM ZnCl2, 1 mM d10-DTT, 10% D2O, 0.01% NaN3) using a Amersham
Pharmacia Biotech PD-10 gel filtration column. The final Raf-CRD-
(149/151) NMR sample contained 0.20 mM of uniformly 15N-enriched
Raf-CRD. The wild type Raf-CRD NMR sample contained 0.28 mM
uniformly 15N-enriched Raf-CRD alone or mixed with wild-type unla-
beled Ras at concentrations ranging from 0.30 to 0.77 mM.
NMR Spectroscopy—NMR experiments were recorded on a Bruker
AMX 500 (500 MHz) spectrometer at 12 °C or a Varian Inova 600 (600
MHz) spectrometer at 25 °C. Two-dimensional 1H-15N heteronuclear
single quantum coherence spectroscopy (HSQC) experiments were per-
formed with pulsed field gradient and water flip-back methods de-
scribed previously (34). Data were acquired with 1024 3 256 complex
data points and a spectral width of 7042.25 Hz for the 1H dimension and
1000 Hz for the 15N dimension on the Bruker AMX 500. HSQC exper-
iments conducted on the Varian Inova 600 spectrometer were acquired
with 1024 3 128 complex data points and a spectral width of 8000 Hz
for the 1H dimension and 1700 Hz for the 15N dimension. NMR data
were processed and analyzed using the program FELIX, version 97.2
(Biosym Technology, San Diego).
NMR Chemical Shift Titration—Two-dimensional 1H-15N HSQC
data were acquired on the Raf-CRD-Ras complexes at 4 different molar
ratios: 1:2.75, 1:1.65, 1:1.1, and 1:0. The final concentration of 15N-Raf-
CRD was 0.28 mM and unlabeled Ras ranged from 0.77 to 0.30 mM.
Samples containing the highest molar ratio (1:2.75) of the Raf-CRD-Ras
complex (0.28:0.77 mM) and Raf-CRD alone (0.28 mM) were prepared
first. To prevent changes in sample volume and buffer composition, the
other two complexes were made by exchanging equal volumes (200 ml)
of these two samples. Proton and 15N resonance assignments of the
Raf-CRD have been obtained previously in this laboratory (26).
RESULTS
The Farnesyl Moiety of Ras Mediates Interactions with the
Raf-CRD—Processed forms of either Ha-Ras or K-Ras have
been reported to be important for stable binding interactions
with the Raf-CRD and for Ras-mediated activation of Raf-1.
Although Ha-Ras and K-Ras possess distinct carboxyl-terminal
lipid modifications, they are both farnesylated at the CAAX
cysteine (20–22). To assess whether farnesylation of Ras alone
is required for stabilization of the Ras/Raf-CRD interaction, we
prepared farnesylated Ha-Ras in vitro using purified bacteri-
ally expressed Ha-Ras-(1–189) and recombinant farnesyl trans-
ferase. Complex formation with the Raf-CRD can be detected
with both farnesylated Ha-Ras and non-farnesylated Ras by
ELISA (Fig. 1A), while only interactions with farnesylated Ras
are observed by a direct binding assay (Fig. 1B). A likely
explanation for the inability to detect non-farnesylated Ras
association to the Raf-CRD in a direct binding assay is the
assays relative insensitivity to weak binding interactions, par-
ticularly those with rapid rates of complex dissociation. Quan-
titation of the Ras/Raf-CRD interaction should aid in reconcil-
ing the apparent differences observed between the ELISA and
direct binding assay. Hence, we have employed a binding assay
based upon the fluorescence technique originally described by
Wittinghofer and co-workers (25). Our method relies on an
increase in apparent fluorescence intensity of mant-dGDP or
mant-GMP-P(NH)P-labeled Ha-Ras upon Raf-CRD binding.
Assuming a simple one-site binding model, we have calculated
an apparent Kd for the farnesylated Ha-Ras-GDP/Raf-CRD
interaction of 33 6 8.4 mM (Fig. 2). In addition, we have ob-
served an apparent Kd for the farnesylated Ha-Ras-GMP-
P(NH)PzRaf-CRD complex of 22 6 6.2 mM (Fig. 2), but we
cannot assert that these modest differences in binding affinity
are statistically significant. This finding is consistent with
previous reports from Hu et al. (10) that the Raf-CRD binds
processed Ha-Ras in a nucleotide independent fashion (23).
FIG. 1. Binding of farnesylated and non-farnesylated Ras to
the Raf-CRD. A, interactions between wild type Raf-CRD fused to GST
and farnesylated or non-farnesylated Ha-Ras were assayed by ELISA.
Assays were performed at least twice in triplicate, as described under
“Experimental Procedures.” A representative data set is shown along
with the resulting standard deviations from the mean. B, Ras binding to
both wild type and mutant Raf-CRD were assessed by a direct binding
assay using in vitro farnesylated and non-farnesylated Ha-Ras, as
described under “Experimental Procedures.” Following separation by
SDS-PAGE and detection by Coomassie R-250, the ratio of Ras bound to
Raf-CRD fused to GST (dark bars) was quantitated by laser densitom-
etry scanning and compared with the ratio of Ras bound to GST alone
(light bars). All assays are performed at least twice in triplicate. Data
from one representative assay and the resulting standard deviations
from the mean are shown.
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More importantly, however, we have determined that fully
processed K-Ras4B binds the Raf-CRD with similar affinity to
that of Ha-Ras that has farnesylation as its only post-transla-
tional modification (data not shown). Due to technical difficul-
ties stemming from solubility limitations of the Raf-CRD, we
were unable to reach binding saturation and therefore not able
to calculate reliable Kd values for unprocessed Ras/Raf-CRD
interactions.
Mutation of a Hydrophobic Surface on the Raf-CRD Impairs
Interactions with Both Farnesylated and Non-farnesylated Ha-
Ras—We recently solved the NMR solution structure of the
Raf-CRD (26) and found it to be structurally similar to CRDs
found in protein kinase C-d and -g isoforms (36–38). We were
intrigued by the existence of a solvent-exposed hydrophobic
patch encompassing residues Leu149, Phe151, and Phe158 on the
surface of the Raf-CRD. We suspected that this hydrophobic
region might be involved in contacting the farnesyl moiety of
Ras, since the Raf-CRD preferentially interacts in vitro with
farnesylated Ras. To test this hypothesis, we disrupted the
hydrophobic patch by creating a L149T/F151Q Raf-CRD
variant.
To assess possible structural perturbations resulting from
mutation of residues Leu149 and Phe151, we evaluated the
HSQC 1H-15N NMR spectral changes of the mutant protein
relative to the wild type Raf-CRD. Results from these analyses
are illustrated in Fig. 3. We observed multiple peaks for some
amide proton resonances in the HSQC 1H-15N spectrum of
Raf-CRD-(L149T/F151Q) (data not shown), suggesting that
this mutant form of Raf-CRD can adopt multiple conformations
in the region of the L149T/F151Q mutation. The Raf-CRD-
(L149T/F151Q) variant, however, shows little if any difference
of 1H and 15N chemical shift values relative to wild type Raf-
CRD throughout the majority of the protein, indicating very
similar global fold and local proton environments. Notable dif-
ferences in chemical shift values are confined to the residues
immediately proximal to and including those mutated, as illus-
trated in Fig. 3, indicating that only the region of the protein
near the mutation is perturbed by the introduction of the
L149T/F151Q mutation.
As shown in Fig. 4, the L149T/F151Q variant showed re-
duced binding to farnesylated Ras relative to wild type Raf-
CRD in both a direct binding assay and a fluorescence based
assay (Fig. 4, A and C). We also observed a reduction in binding
of the Raf-CRD-(L149T/F151Q) variant to non-farnesylated
Ha-Ras, as detected by both ELISA and fluorescence-based
assays (Fig. 4, B and C), indicating that interactions with both
farnesylated and non-farnesylated Ras are, at least in part,
mediated by hydrophobic contacts.
Mutation of a Hydrophobic Surface on the Raf-CRD Retains
Interactions with 14-3-3z and Phosphatidylserine—In addition
to binding Ras, the Raf-CRD also interacts with 14-3-3 and PS
(27, 28). Therefore, to assess whether this mutation specifically
impairs interactions with Ras or also affects binding to 14-3-3
and PS, we employed ELISAs and competition binding studies,
respectively. The Raf-CRD-(L149T/F151Q) displays impaired
interactions with farnesylated Ha-Ras, processed K-Ras4B
(data not shown), and unprocessed Ha-Ras. As shown in Fig. 5,
this impairment is specific for Ras, as the Raf-CRD-(L149T/
F151Q) variant does not effect binding to 14-3-3z as detected by
ELISA (Fig. 5A) or the ability of PS to compete with 14-3-3 for
contacting the Raf-CRD in a competition binding assay where
we assessed the amount of 14-3-3 bound to Raf-CRD in the
presence or absence of PS (Fig. 5B). The previously described
Raf-CRD-(R143E/K144E) mutant was included in these assays
as a negative control (28).
Raf kinase Activation—Our identification of a Raf-CRD var-
iant that is selectively impaired in Ras, but not phosphatidyl-
serine or 14-3-3z, binding provides a novel reagent to assess the
affect of Ras-Raf-CRD interactions in mediating Raf-1 activa-
tion. For these analyses, we introduced L149T/F151Q into full-
length Raf-1 and compared the ability of Ras to stimulate the
kinase activity of equal amounts of wild type and mutant
protein Raf-1 protein in COS cells. The data are shown in Fig.
6. We have previously shown that the Raf R143E/K144E mu-
tant is defective in both 14a3-3 and PS binding and possesses
enhanced transforming potential (28), and proposed that 14-3-3
acts as a negative regulator of Raf-1 function by this interac-
tion. In contrast, the Raf(L149T/F151Q) mutant that is defec-
tive in Ras/Raf-CRD interactions, exhibits no transforming
potential and a severely impaired kinase activity in the pres-
FIG. 2. Fluorescence-based quantitation of binding interac-
tions between farnesylated and non-farnesylated Ha-Ras with
the Raf-CRD. Fluorescence assay based on an increase in apparent
fluorescence intensity of mant-dGDP or mant-GMP-P(NH)P-labeled
Ha-Ras upon the addition of Raf-CRD. l, denotes farnesylated Ras-
GMP-P(NH)P; E, farnesylated Ras-GDP; f, non-farnesylated Ras-
GMP-P(NH)P; and M, non-farnesylated Ras-GDP. Apparent Kd values
for binding of Raf-CRD to either farnesylated Ras-GMP-P(NH)P or
farnesylated Ras-GDP are 22 mM (66.2 mM) and 33 mM (68.4 mM),
respectively.
FIG. 3. NMR analysis of Raf-CRD-(149/151). Backbone CPK model
of the Raf-CRD generated with InsightII (MSI) using the PDB coordi-
nates (PDB number 1FAR) from our previously determined NMR solu-
tion structure (26) with residues that possess chemical shift and/or
intensity changes in 1H-15N HSQC spectra upon mutation of residues
149 and 151 highlighted. Residues (149, 150, 151, 152, 158, and 159)
that show HN chemical shift changes greater than 0.03 ppm in 1H or
more than 0.3 ppm in 15N are shown in red. Residues (145, 146, 148,
156, 157, and 160) highlighted in pink, show either intensity changes
and/or observable HN chemical shift changes of greater than 0.02 ppm
in 1H or 0.2 in 15N dimensions.
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ence of activated Ras. While the basal kinase activities of wild
type and L149T/F151Q mutant Raf-1 showed no significant
differences in this assay, the very low unstimulated activities
make it difficult to draw a firm conclusion regarding the effect
that the L149T/F151Q mutation has on the basal activity of the
kinase.
NMR Chemical Shift Mapping—Although substitution of
residues Leu149 and Phe151 results in impaired interaction with
Ras, it was not clear whether the hydrophobic patch containing
these residues is a direct point of contact with Ras or if the
mutations perturb other residues/regions of the Raf-CRD
involved in binding Ras. To elucidate the residues involved in
fused to GST and non-farnesylated Ha-Ras were also assayed by
ELISA. Ras bound to Raf-CRD fused to GST is denoted by dark bars
whereas Ras bound to GST alone is represented by light bars. Assays
were performed at least twice in triplicate, as described under “Exper-
imental Procedures.” A representative data set is shown along with the
resulting standard deviations from the mean. C, fluorescence assay
based on an increase in apparent fluorescence intensity of mant-dGDP
labeled Ha-Ras upon the addition of Raf-CRD. l, denotes farnesylated
Ras and wild type Raf-CRD; E, indicates non-farnesylated Ras and wild
type Raf-CRD. f, denote farnesylated Ras and Raf-CRD-(149/151); M,
non-farnesylated Ras-(L149T/F151Q) mutant Raf-CRD.
FIG. 4. Interactions of Ha-Ras-GDP with wild type or mutant
Raf-CRD. A, Ras-binding properties of mutant Raf-CRD were assessed
by a direct binding assay using in vitro farnesylated Ha-Ras, as de-
scribed under “Experimental Procedures.” Following separation by
SDS-PAGE and detection by Coomassie R-250, the ratio of Ras bound to
Raf-CRD fused to GST (dark bars) was quantitated by laser densitom-
etry scanning and compared with the ratio of Ras bound to GST alone
(light bars). All assays are performed at least twice in triplicate. Data
from one representative assay and the resulting standard deviations
from the mean are shown. B, interactions between mutant Raf-CRD
FIG. 5. The mutant Raf-CRD-(L149T,F151Q) retains interac-
tions with 14-3-3z and phosphatidylserine. A, the ability of the
Raf-CRD-(L149T/F151Q) variant to interact with 14-3-3z was assessed
by ELISA as described under “Experimental Procedures.” Dark bars (f)
symbolize Raf-CRD and the light bars (M) represent interactions be-
tween GST and 14-3-3. B, since phosphatidylserine can compete with
14-3-3z for binding to the Raf-CRD,2 we assessed the ability of the
Raf-CRD-(L149T/F151Q) variant to bind 14-3-3 in the presence of phos-
pholipids. The amount of 14-3-3 captured in the presence (f) and
absence (M) of PS is plotted here. Assays were performed three times in
duplicate. The previously described R143E/K144E mutant was included
in these assays as a negative control.
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interactions between the Raf-CRD and Ras, we evaluated
HSQC 1H-15N NMR spectral changes associated with the
binding of unprocessed Ha-Ras-GDP-(1–166) to 15N-enriched
Raf-CRD.
The function of the 15N isotope is to remove NMR signals
from all protons not attached to 15N, thereby providing a two-
dimensional NMR spectrum that contains HN peaks from only
those protons attached to an 15N nucleus. The ability to selec-
tively observe amide resonances in 15N-enriched proteins pro-
vides a site-specific probe for every residue with the exception
of proline. Hence, observation of spectral changes associated
with the HN peaks of 15N-enriched Raf-CRD upon Ras binding,
elucidates residues in the Raf-CRD perturbed upon Ras bind-
ing (Fig. 7).
These heteronuclear NMR studies were conducted at four
different stoichiometric Raf-CRD:Ras ratios ranging from
1:2.75 to 1:0. The 1H-15N chemical shifts and HN intensity
variations observed upon Ras binding, as described below,
showed trends that were consistent with an increasing concen-
tration of Ras.
As shown in Fig. 8, most of the chemical shift differences
observed in 1H-15N HSQC spectra of 15N-Raf-CRD and the
Ras-GDPzRaf-CRD complex are localized to Raf-CRD residues
144, 145, 148–150, 158–164, and 174–176. 1H chemical shift
changes greater than 0.02 ppm were observed for residues 144,
145, 148–150, 158–160, 174, and 175. Residues 161, 163, 164,
and 176 showed slightly smaller chemical shift changes (great-
er than 0.015 ppm) compared with the rest of the peaks, which
exhibited changes of less than 0.01 ppm. The average change of
the other 38 residues was 0.0001 ppm.
The same trend was observed in the 15N chemical shift
changes. The 15N-chemical shifts corresponding to residues
145, 148, 149, 158, 163, and 175 were shifted more than 0.2
ppm and residues 136, 150, 162, 174, and 183 differed by more
than 0.1 ppm in the presence and absence of a 2.75-fold excess
of Ras. The average chemical shift variation for the other 41
residues was 0.00018 ppm. Uniformly reduced peak intensities
(;55%) were also observed for several peaks when the 1H-15N
HSQC spectrum of the 1:2.75 Raf-CRDzRas complex was com-
pared with the spectrum of the Raf-CRD alone. The largest
variation in intensity changes for the HN peaks, however, were
observed for residues 141, 145, 148–150, 158, and 170; 141 and
150 were the only residues showing intensity changes without
corresponding observable chemical shift alterations. Residues
showing chemical shift and/or intensity changes in 1H-15N
HSQC spectra upon binding of unprocessed Ras-GDP to 15N-
enriched Raf-CRD are highlighted on the ribbon diagram of the
Raf-CRD in Fig. 8.
DISCUSSION
In this work, we have characterized binding contacts impor-
tant for interactions between Ras and the Raf-CRD and Ras-
mediated Raf-1 activation. In particular, post-translational
FIG. 6. Effect of the 149/151 mutation on Ras-mediated Raf-1
activation. 1 mg of pCGN-hyg vector encoding HA-tagged wild type or
mutant Raf proteins were co-transfected with pCGN-hyg Ha-Ras 61L
into COS-7 cells using LipofectAMINE (Life Technologies, Inc.). After
48 h the cells were shifted to 1% serum and incubated overnight. The
cells were then lysed and examined for the expression of Raf protein by
Western blot using an anti-HA antibody (BabCo). Raf-1 kinase activity
was examined by immunoprecipitating the Raf protein with C-12 poly-
clonal antisera (Santa Cruz) and adding recombinant MEK, ERK, and
MBP substrate to generate a coupled assay for 32P incorporation into
MBP. The data presented are representative of two separate assays.
FIG. 7. NMR spectral changes resulting from Ras/15N-Raf-CRD
interaction. Superposition of two-dimensional 1H-15N HSQC spectra
of uniformly 15N-enriched Raf-CRD in the presence (blue) and absence
(red) of unlabeled Ras-GDP. The concentration of 15N-enriched Raf-
CRD was 0.28 mM in both samples and that of unlabeled Ras in complex
was 0.77 mM. Raf-CRD residues that show distinguished changes in 1H
and 15N chemical shift and/or intensity are indicated. Changes in spec-
tra increased in proportion as the molar ratio of Raf-CRD:Ras increased
from 1:1.1 to 1:2.75.
FIG. 8. Residues in Raf-CRD perturbed upon binding non-far-
nesylated Ras. Ribbon model of the Raf-CRD generated with InsightII
(MSI) using the PDB coordinates (PDB number 1FAR) derived from our
recently determined NMR solution structure (26). Residues showing
chemical shift and/or intensity changes in 1H-15N HSQC spectra upon
binding of unprocessed Ras-GDP to 15N-enriched Raf-CRD are high-
lighted. Residues (144, 145, 148–150, 158–160, 163, and 174–175) that
show HN chemical shift changes greater than 0.02 ppm in 1H or more
than 0.2 ppm in 15N are shown in red. Residues 136, 141, 161, 162, 164,
170, 176, and 183, highlighted in pink, show either intensity changes
and/or observable HN chemical shift changes of greater than 0.015 ppm
in 1H or 0.1 ppm in 15N dimensions.
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lipid modification of Ras imparts higher affinity interactions
with the Raf-CRD. The binding of post-translationally modified
Ras to Raf-1 has been shown to be critical for membrane re-
cruitment of Raf-1. However, it also appears important for
directly regulating Raf-1 activity, as Stokoe and McCormick
(12) have shown that purified processed K-Ras-GTP, but not
unmodified K-Ras-GTP or farnesylated K-Ras-GDP, is capable
of stimulating Raf-1 to the same extent as activated processed
Ha-Ras using an in vitro reconstitution system (20). Moreover,
in a cell-free assay, fully processed K-Ras has been shown to be
more active than unmodified K-Ras in Ras-dependent ERK
kinase stimulator-mediated activation of MAP kinase (21, 22).
Carboxyl-terminal processing differs in Ha-, K-, and N-Ras,
and involves multiple modifications, including farnesylation,
palmitoylation, carboxyl-terminal cleavage, and carboxyl-
methylation (24). However, processed forms of both Ha-Ras
and K-Ras can promote Ras-mediated activation of Raf-1, with
the only common lipid modification being farnesylation. These
results suggest that the farnesyl moiety alone may be critical
for promoting Ras-dependent activation of Raf-1. To character-
ize post-translational modification(s) of Ras important for bind-
ing to the Raf-CRD, we prepared full-length farnesylated Ha-
Ras, and found that farnesylation of Ras alone was sufficient to
confer higher affinity association with the Raf-CRD, relative to
bacterially expressed unprocessed Ras. Consistent with this
observation, McGeady et al. (35) have shown that farnesylation
of Ha-Ras is sufficient to cause activation of MAP kinase in a
cell- and membrane-free Ras-dependent MAP kinase activation
system (35). These observations, in combination with earlier
findings that post-translationally modified Ha-Ras confers sta-
ble association with the Raf-CRD (10), provide additional sup-
port that it is the farnesyl moiety that conveys this additional
binding affinity to the Raf-CRD, rather than any other form of
post-translational modification and may play a critical role in
Ras-dependent activation of Raf-1.
We have also examined non-farnesylated Ha-Ras’ interac-
tions with the Raf-CRD and determined that both GDP- and
GMP-P(NH)P-bound Ha-Ras associate with the Raf-CRD. Our
results do indicate, however, that non-processed forms of Ras
bind the Raf-CRD with at least 10-fold lower affinity relative to
farnesylated Ras. These observations agree with our previous
data that demonstrated binding of non-processed Ras to the
Raf-CRD (9), but is contrary to reports that Ras must be pro-
cessed in order to bind the Raf-CRD (10). It is likely that the
weak interaction between non-processed Ras and the Raf-CRD
was beyond the detection limits of the assay employed by Hu et
al. (10).
The relatively weak affinity of farnesylated Ras-GTP for the
Raf-CRD (about 20 mM) was originally a point of concern since
the levels of Raf-1 in normal cells is much lower than this
value. The very tight binding of Ras-GTP and the first Ras-
binding site in Raf (RBS-1), however, should compensate for
this weak interaction by increasing the effective concentration
of the Raf-CRD for interaction with Ras. Additionally, our
results suggest that the Raf-CRD, unlike Raf-RBS1, does not
appear to have a strong preference for binding of GTP- or
GDP-bound farnesylated Ras. Moreover, binding interactions
between the Raf-CRD and Ras have a greater dependence upon
the nucleotide bound state of Ras when Ras is not farnesylated.
Our data suggests that there could be as much as a 2–5-fold
preference for Ras-GMP-P(NH)P relative to Ras-GDP when
Ras is not farnesylated. This is consistent with our earlier
observations (9) and findings that mutations in regions of Ras
flanking switch 1, interfere with Ras/Raf-CRD interactions
(41). However, GTP-dependent binding was not observed in our
studies of Raf-CRD interactions with farnesylated Ras as well
as in earlier studies conducted with processed Ha-Ras (10). A
possible explanation for this apparent discrepancy is that far-
nesylation of Ras confers additional binding affinity for the
isolated Raf-CRD independent of Ras’ activated state. Hence,
the modest GTP-preference observed in the unprocessed form
of Ras may not be detectable in the presence of the additional
binding energy supplied, in a nucleotide independent manner,
upon farnesylation or processing.
While some information currently exists on regions of Ras
important for association with the Raf-CRD, very little is
known about Raf-CRD residues that facilitate binding to Ras.
To elucidate residues of the Raf-CRD important for Ras bind-
ing, we prepared Raf-CRD mutants and assessed the binding of
these mutants to both farnesylated and non-farnesylated Ha-
Ras. We also employed NMR approaches to map the binding
interface between Ha-Ras and the Raf-CRD. A Raf cysteine-
rich domain variant that disrupts a hydrophobic patch on the
surface of the Raf-CRD was generated. This Raf-CRD-(149/151)
variant is impaired selectively in its ability to bind Ras, but not
phosphatidylserine or 14-3-3z. Moreover, the Raf-CRD-(149/
151) is defective for activation by Ras. This result indicates
that Ras interactions with the Raf-CRD act to positively regu-
late Raf-1 function, perhaps by facilitating release of negative
regulatory constraints by the dissociation of 14-3-3 and/or in-
tramolecular interactions (3, 28, 39). This, in turn, may facilitate
Raf-1 kinase activation. We cannot exclude the possibility, how-
ever, that the Leu149-Phe151 mutation disrupts positive regula-
tory interactions with an, as of yet, uncharacterized ligand.
The Raf-CRD-(149/151) variant binds with reduced affinity
to both the farnesylated and non-farnesylated forms of Ras.
These findings indicate that the hydrophobic surface patch
does not specifically recognize the farnesyl group but is also
important for binding interactions with an epitope present on
non-farnesylated Ras. Moreover, our observations that resi-
dues 148–150 and 158–164 were perturbed in NMR chemical
shift mapping experiments provide further support of the im-
portance of this hydrophobic region in mediating binding con-
tacts with unprocessed Ras. Although spectral changes are also
observed for Raf-CRD residues 144 and 145, our recent char-
acterization of the K144E Raf-CRD variant indicates that this
mutation does not reduce Ras binding to the Raf-CRD (28).2
Hence, the observed spectral changes associated with residues
144 and 145 may reflect changes in their chemical environment
due to Ras binding at nearby residues. The NMR data suggests
that one additional region may be involved in contacting un-
processed Ras, as residues 174–177 are also sensitive to the
binding of Ha-Ras-GDP to the Raf-CRD. However, it is possible
that the chemical shift differences in this region are due to
indirect effects of Ras binding since we have mutated Thr178 of
the Raf-CRD and seen no effects on Ras, 14-3-3, or phosphati-
dylserine binding (data not shown).
While we and others have identified Ras regions important
for binding the Raf-CRD (10, 11), this report now characterizes
residues within the Raf-CRD that are involved in contacting
Ras. Additionally, we have shown that disruption of this region
of the Raf-CRD that contacts Ras results in a form of the Raf-1
kinase that is biologically inactive, strongly suggesting a ne-
cessity for direct contact between Ras and the Raf-CRD for
Ras-mediated activation of Raf-1. Furthermore, although the
non-farnesylated form of Ras clearly contains a subset of bind-
ing determinants for the Raf-CRD, our data indicate that the
farnesyl moiety confers higher affinity interactions with the
Raf-CRD.
2 G. J. Clark, J. K. Drugan, S. Ghosh, K. L. Rossman, R. M. Bell, C. J.
Der, and S. L. Campbell, submitted for publication.
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It is unclear at this time if the farnesyl group directly inter-
acts with the Raf-CRD and/or structures an epitope on Ras (e.g.
the COOH terminus) such that it confers additional binding
affinity for the Raf-CRD. However, it is clear that the higher
affinity binding of processed Ras to the Raf-CRD is mediated by
the addition of the farnesyl moiety, rather than further proc-
essing (carboxyl-terminal proteolysis, methylation, and palmi-
toylation), and that the Raf-CRD recognizes a subset of Ras-
GTP binding determinants distinct from those that interact
with RBS-1 (10, 11, 42).
The data presented here help to elucidate the regions of the
Raf-CRD that are involved in Ras binding and subsequent
Raf-1 activation events following membrane localization. More-
over, our observation that higher affinity interaction between
the Raf-CRD and Ras requires Ras farnesylation elucidates
additional regions of Ras that are essential for interactions
with the Raf-CRD. Although the farnesyl moiety often is
thought to facilitate membrane localization of proteins, data
from Silvius and l’Heureux (43) demonstrate that membrane
anchorage by farnesylated cysteines is rapidly reversible, un-
like the COOH-terminal palmitoyl moieties of Ras that have
high affinity for bilayers (44). Thus, one can envision a mech-
anism by which palmitoylation of Ras anchors it to the plasma
membrane, while the farnesyl group is then at least partially
available to interact with Ras’ targets such as the Raf-1 cys-
teine-rich domain. We are currently testing this hypothesis.
In addition to farnesylated Ras, we and others have demon-
strated that the Raf-CRD binds phosphatidylserine and 14-3-3
proteins (27, 28).2 We postulated that Ras interaction with the
Raf-1 cysteine-rich domain may modulate contacts with PS and
14-3-3 to mediate Raf-1 activation. In particular, exposure of
the Ras-binding elements in the Raf-CRD may require release
of 14-3-3 proteins and/or intramolecular negative regulatory
interactions, as described elsewhere (3, 28, 40). In summary,
interactions between Ras and the Raf-1 cysteine-rich domain
may induce the removal of negative regulatory action in the
Raf-1 NH2 terminus and consequently, facilitate Raf-1 activa-
tion by additional events such as phosphorylation of select
residues in Raf-1. The identification of Raf-CRD mutations that
selectively interfere with Ras, 14-3-3, or phosphatidylserine,
will provide valuable reagents to further test this hypothesis.
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